Novo Nordisk to invest more than 100 million euro in production plants in Chartres, France

The expansions will help the company to meet the increasing worldwide demand for its diabetes medicines.

The new facilities will be built on Novo Nordisk's existing 31,000 m2 site in Chartres, which produces a range of the company's insulin products as well as FlexPen, the world's most widely used insulin injection device. The products are exported to more than 40 countries all over the world.

Novo Nordisk has invested 300 million euros in France over the past 15 years and today employs 1,100 employees at the site. The planned expansion is estimated to create around 250 new jobs once the facilities are fully operational within three to four years.

"Novo Nordisk has been operating in France for more than 50 years," says Lars Rebien Sørensen, president and CEO of Novo Nordisk. "Over the years we have built a very strong organisation in France, and our site in Chartres is today one of our most important strategic production sites. With the coming expansion we will further strengthen Chartres' position in our global product supply organisation."

In addition to the 1,100 employees in Chartres, Novo Nordisk employs 300 people in its affiliate in Paris, which is responsible for the company's medical, regulatory and commercial activities in France.